Home » Topics » BioWorld Science

BioWorld Science
RSS

CEPI provides funding to support Themis' development of chikungunya vaccine MK-CHIK

June 4, 2019

FDA clears Nouscom's IND for phase I trial of NOUS-209 in MSI solid tumors

June 4, 2019

Qurient reports phase IIa data on telacebec for TB

June 4, 2019

Phase III BLOCKSTONE study of Xofluza to prevent influenza infection meets primary endpoint

June 4, 2019

First clinical data for Daiichi's IDH inhibitor DS-1001 presented for recurrent glioma

June 4, 2019

Oligomerix continues NIH-funded work on tau oligomer inhibitor

June 4, 2019

Kyowa Hakko Kirin initiates Japanese phase III trial of brodalumab in systemic sclerosis

June 4, 2019

Jeil Pharmaceutical divulges new H+/K+-ATPase inhibitors

June 4, 2019

Polish researchers identify 5-HT6 receptor antagonists

June 4, 2019

Kissei Pharmaceutical describes CGRP receptor antagonists

June 4, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.